Abstract:Background: Acute bronchitis, frequently emerging with the common cold is one of the most frequent causes of primary care consultations. It is a self-limiting disease which poses both high symptom burden to individuals and high financial burden to society. It is largely a viral disease (~50 % rhinovirus infection), but no causal (antiviral) treatment exists. Antibiotics, mucoactive agents, antihistamines, antitussives, decongestants are most often used but without evidence from randomized controlled trials (RC… Show more
“…The combinations are approved medicinal products in several countries and are recommended by the German guidelines for the treatment of acute cough 1 . In preclinical in vitro and in vivo studies anti-inflammatory characteristics and normalizing effects regarding mucus viscosity have also been shown [11][12][13][14] . A systematic review and metaanalysis confirmed that ivy-, primrose-or thyme-based remedies reduce both frequency and severity of acute cough 15 .…”
Objective: Efficacy and safety of an oral thyme/ivy syrup for the treatment of acute cough was previously demonstrated in a randomized clinical trial. Here, we present real-life data from a pharmacybased, observational study on the effectiveness and tolerability of another thyme/ivy combination (BNO 1200, Bronchipret drops). Methods: This observational, prospective, uncontrolled study was conducted in 305 German pharmacies. Cough and associated symptoms, cough severity and health related quality of life (HRQoL) were assessed at baseline, after 4 days and at individual end of treatment (EoT) in patients with acute cough due to upper respiratory tract infections who bought BNO 1200. Patients took BNO 1200 until resolution of cough and completed three validated questionnaires: patient-adapted Bronchitis Severity Score (BSS), cough severity visual analogue scale (VAS) and the Leicester Cough Questionnaire (LCQacute). They also rated speed of onset of treatment action on a VAS and tolerability. Results: A total of 749 patients participated in the study; 730 were included in the analysis. Mean treatment duration was 7.0 ± 3.6 days. Symptom severity assessed by BSS improved from 8.7 ± 3.8 score points (baseline) to 2.4 ± 2.6 at EoT (p < .0001). Clinically relevant improvements (MCID ¼ 17 mm) in cough severity were reported by 87.2% of patients at EoT. HRQoL improved significantly (12.2 ± 3.3 points at baseline vs. 18.5 ± 2.7 at EoT; p < .0001), exceeding the MCID (¼2 points) in 90.0% of patients. Tolerability was rated "good" or "very good" by 98.0% of patients. No adverse drug reactions were reported. Conclusion: Patients with acute cough taking BNO 1200 had a significant reduction in BSS, cough severity and improvement in HRQoL confirming RCT data with the syrup formulation. BNO 1200 was well tolerated.
“…The combinations are approved medicinal products in several countries and are recommended by the German guidelines for the treatment of acute cough 1 . In preclinical in vitro and in vivo studies anti-inflammatory characteristics and normalizing effects regarding mucus viscosity have also been shown [11][12][13][14] . A systematic review and metaanalysis confirmed that ivy-, primrose-or thyme-based remedies reduce both frequency and severity of acute cough 15 .…”
Objective: Efficacy and safety of an oral thyme/ivy syrup for the treatment of acute cough was previously demonstrated in a randomized clinical trial. Here, we present real-life data from a pharmacybased, observational study on the effectiveness and tolerability of another thyme/ivy combination (BNO 1200, Bronchipret drops). Methods: This observational, prospective, uncontrolled study was conducted in 305 German pharmacies. Cough and associated symptoms, cough severity and health related quality of life (HRQoL) were assessed at baseline, after 4 days and at individual end of treatment (EoT) in patients with acute cough due to upper respiratory tract infections who bought BNO 1200. Patients took BNO 1200 until resolution of cough and completed three validated questionnaires: patient-adapted Bronchitis Severity Score (BSS), cough severity visual analogue scale (VAS) and the Leicester Cough Questionnaire (LCQacute). They also rated speed of onset of treatment action on a VAS and tolerability. Results: A total of 749 patients participated in the study; 730 were included in the analysis. Mean treatment duration was 7.0 ± 3.6 days. Symptom severity assessed by BSS improved from 8.7 ± 3.8 score points (baseline) to 2.4 ± 2.6 at EoT (p < .0001). Clinically relevant improvements (MCID ¼ 17 mm) in cough severity were reported by 87.2% of patients at EoT. HRQoL improved significantly (12.2 ± 3.3 points at baseline vs. 18.5 ± 2.7 at EoT; p < .0001), exceeding the MCID (¼2 points) in 90.0% of patients. Tolerability was rated "good" or "very good" by 98.0% of patients. No adverse drug reactions were reported. Conclusion: Patients with acute cough taking BNO 1200 had a significant reduction in BSS, cough severity and improvement in HRQoL confirming RCT data with the syrup formulation. BNO 1200 was well tolerated.
“…Die Tatsache, dass der Erkältungshusten auch ohne Therapie spontan abklingt, soll nicht bedeuten, dass die häufig erheblichen Symptome und der Leidensdruck nicht behandelt werden sollen. In den letzten Jahren wurde für mehrere pflanzliche Präparate Pflanzliches Präparat , für Ambroxol Ambroxol und für Dextromethorphan Dextromethorphan eine Überlegenheit gegenüber Plazebo für den akuten Husten im Rahmen viraler Infekte gezeigt [ 3 , 4 ].…”
Section: Klassifizierung Des Hustensunclassified
“…Häufigste Ursache des akuten (bis zu 3 Wochen Dauer) oder subakuten (3)(4)(5)(6)(7)(8) Hustens ist ein viraler Infekt, der bei ansonsten gesunden Personen meist spontan abklingt. Einige pflanzliche Kombinationspräparate, Ambroxol und das Antitussivum Dextromethorphan erleichtern den Husten und verkürzen dessen Dauer.…”
“…Nur bei Vorhandensein von Alarmzeichen ("red flags") -Dyspnoe, Hämoptoe, hohes Fieber, multimorbide, immunsupprimierte und ältere Patientensind weiterführende Untersuchungen erforderlich. In den letzten Jahren konnte für mehrere pflanzliche Präparate und für Dextrometorphan eine Wirksamkeit gegenüber Placebo für den akuten Husten im Rahmen von Erkältungsinfekten gezeigt werden [3,4]. Die Initiative "Klug entscheiden" der Deutschen Gesellschaft für Innere Medizin (DGIM) rät für den Regelfall dringend von einer antibiotischen Behandlung der akuten Bronchitis ab [5].…”
WAS IST NEU?Klassifizierung des Hustens Die Klassifizierung ist jetzt dreistufig: ▪ akuter Husten bis zu 2 Wochen Dauer (meistens bei Erkältung) ▪ subakuter Husten: 3 -8 Wochen Dauer ▪ chronischer Husten: über 8 Wochen Dauer Chronischer idiopathischer Husteneine neue Hypothese Der chronische idiopathische Husten (CIH, in früheren Leitlinien: chronisch persistierender Husten) wird durch eine Hypersensitivität des Hustenreflexes verursacht. Häufig wird diese Hypersensitivität durch einen unscheinbaren viralen Infekt ausgelöst, sie kann Jahre oder Jahrzehnte anhalten. Frauen sind doppelt so häufig betroffen wie Männer. Gastroösophagealer Reflux, chronische Rhinosinusitis, laryngeale Hyperreagibilität sind nicht die Auslöser, sondern nur Trigger des Hustens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
